Partners delaying purchase of Care New England

John Gregory | | Health Exec | Economics

Boston-based Partners HealthCare is holding off on its acquisition of Rhode Island’s No. 2 hospital system, Care New England, after the latter reported heavy losses.

Care New England has lost $46 million so far this fiscal year, on top of $53 million in losses in 2016, and recently had its bond rating downgraded. Partners had announced the proposed merger in April, but is now set to meet with Care New England in September or October the re-evaluate the deal.

“The devil is in the details in the assumptions, but we’d like to see them showing us pretty near-term break even, and getting to a 1 to 2 percent margin within three years or so,” Partners CFO Peter Markell said to the Boston Business Journal.

WPRI reported if Partners passes, another Rhode Island-based system may make Care New England an offer. Read more at the link below:

Partners holding off on Care New England takeover due to financial concerns

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.